Ascentage Pharma Group International (NASDAQ:AAPG) Shares Down 6% – Time to Sell?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) fell 6% on Monday . The company traded as low as $17.19 and last traded at $17.1850. Approximately 2,433 shares changed hands during trading, a decline of 64% from the average session volume of 6,834 shares. The stock had previously closed at $18.28.

Analyst Ratings Changes

AAPG has been the subject of a number of research analyst reports. B. Riley Financial assumed coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 target price for the company. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. Finally, BTIG Research restated a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Price Performance

The stock has a 50-day moving average of $18.23 and a two-hundred day moving average of $20.96. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million during the quarter. Equities research analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.26 earnings per share for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently bought and sold shares of AAPG. Citadel Advisors LLC purchased a new position in Ascentage Pharma Group International in the third quarter worth about $383,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International during the second quarter valued at approximately $391,000. Finally, UBS Group AG increased its position in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares in the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.